Bristol-Myers Squibb Foundation Announces Funding of More Than $1.17 Million to Bridge Gaps in Hepatitis C Awareness, Prevention and Care in China, India and Taiwan
PRINCETON, N.J.- The Bristol-Myers Squibb Foundation today announced funding of more than $1.17 million, focused on hepatitis C prevention and education and the mitigation of the disease in China, India, and Taiwan. The funding is part of Delivering Hope, an umbrella program for Bristol-Myers Squibb’s (NYSE: BMY) efforts in the areas of hepatitis awareness, prevention and care. Organizations receiving funding are:
* The Liver Disease Prevention and Treatment Research Foundation (Taiwan) will create a training program for patients and community-based health care providers in detection, care, and management of patients and provide access to treatment in remote areas.
* The Liver Foundation/West Bengal (India) will conduct a survey of the impact of liver disease and hepatitis C and utilize the findings to inform public health policy and foster prevention and awareness activities in at risk populations.
* The Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital (Taiwan) will initiate a comprehensive intervention program focusing on prevention, early diagnosis, and medical management.
* The National Liver Foundation (India) will focus on improvement of hepatitis C screening, including the addition of more sensitive tests, and will create education and awareness programs for local communities.
* The Shanghai Charity Foundation (China) will focus on improving education, screening rate and accuracy, and disease therapy.
“The programs these organizations propose exemplify our Bristol-Myers Squibb Foundation mission of addressing health disparities in communities where the need is greatest,” said John Damonti, president, Bristol-Myers Squibb Foundation. “Through these programs, we anticipate significant improvement in our understanding of how to best address the hepatitis C health challenges in China, India, and Taiwan. We envision key learnings from these programs will be applied in other countries.”
In keeping with the Bristol-Myers Squibb Foundation’s commitment to sharing lessons learned, funding recipients will prepare a comprehensive final report at the completion of their projects. These reports will be shared with the hepatitis C community to enhance the body of knowledge on hepatitis prevention, care, and support. Earlier this week, Delivering Hope organizations, experts and national policy makers from Asia, the United States, and Southern Africa initiated the reporting process by meeting for a BMS Foundation Delivering Hope Learning and Sharing Workshop to discuss community-based education and outreach interventions. At the two-day workshop, attendees shared best practices from their home countries and attendees learned new skills to apply in their home countries.
About Hepatitis C 1
Hepatitis C is a virus that infects the liver and is transmitted through direct contact with blood. An estimated 170 million people worldwide are infected with hepatitis C and, of these, 94.5 million people live in the Asia Pacific region. One to five percent of people with chronic infection will develop liver cancer. Although there is no vaccine to prevent hepatitis C, it is a curable disease.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.